Clinical trial / 2015
Neither EPA-enriched nor DHA-enriched omega-3 fatty acids were superior to placebo for treating major depressive disorder.
A 2-site trial randomized 196 adults with DSM-IV major depressive disorder to 8 weeks of EPA-enriched omega-3 (1,000 mg/d), DHA-enriched omega-3 (1,000 mg/d), or placebo. All three groups exhibited statistically significant improvements in HDRS-17, QIDS-SR-16, and CGI-S scores (P < .05), but neither active preparation separated significantly from placebo (P > .05). Response rates were 40%-50% and remission rates were approximately 30% across all treatments without significant differences between groups.
- Study type
- Double-blind, placebo-controlled, randomized clinical trial
- Who was studied
- 196 adults with DSM-IV major depressive disorder and baseline HDRS-17 score ≥ 15
- What was measured
- Change in HDRS-17, QIDS-SR-16, and CGI-S scores, response, and remission rates
THE PAPER
A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression.
Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K, Martinson MA, Hyman Rapaport M. J Clin Psychiatry, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.